SciELO - Scientific Electronic Library Online

 
vol.35 número3Reacciones adversas asociadas a vacunas contra la COVID-19 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


CES Medicina

versión impresa ISSN 0120-8705

Resumen

GAVIRIA-MENDOZA, Andrés et al. Prescription profile of antiarrhythmic drugs in a group of patients in Colombia. CES Med. [online]. 2021, vol.35, n.3, pp.213-229.  Epub 14-Mar-2022. ISSN 0120-8705.  https://doi.org/10.21615/cesmedicina.5308.

Objective:

To determine the prescription patterns of antiarrhythmic drugs and variables associated with their use in a population of patients affiliated with the Colombian Health System.

Methods:

A cross-sectional study was performed on a population database with patients who received antiarrhythmics from March to May 2016. Sociodemographic, pharmacological and comedication variables were included. SPSS-24 was used for data analysis using X2 tests and multivariate analyses.

Results:

In total, 2772 patients were treated with antiarrhythmics in the evaluated period. The mean age was 70.1 ± 13.1 years, and 51.2% were women. In total, 79.4% used a β-blocker, 58.5% amiodarone and 2.9% a calcium channel blocker. Moreover, 1192 (43.0%) patients were prescribed a single antiarrhythmic, and 1580 (57.0%) received two or more. There were 2603 patients (93.9%) with comedication, including lipid-lowering drugs (62.6%), inhibitors of the renin angiotensin aldosterone system (62.6%) and antiplatelet drugs (42.0%). Age older than 65 years increased the probability of comedication (odds ratio [OR]: 2.48; 95% confidence interval [95% CI]: 1.59-3.85), and the risk was proportional to age. We identified 1364 patients treated with conditional risk medications for QT prolongation (49.2%), 68 with a possible risk (2.5%) and 171 (6.2%) with a known risk.

Conclusion:

Antiarrhythmic drugs recommended by clinical practice guidelines are mainly used; however, risk interactions interactions of QT prolongation were identified and should be taken into account by physicians to avoid adverse events or complications.

Palabras clave : adrenergic beta-antagonists; anti-arrhythmic agents; arrhythms cardiac; atrial fibrillation; long QT syndrome.

        · resumen en Español     · texto en Inglés     · Inglés ( pdf )